| scholarly article | Q13442814 |
| P2093 | author name string | Jihong Han | |
| Hideaki Nakaya | |||
| Antonio M. Gotto | |||
| Andrew C. Nicholson | |||
| Barbara D. Summers | |||
| David P. Hajjar | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor | Q24323199 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation | Q29620219 | ||
| Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. | Q31452265 | ||
| PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway | Q31793810 | ||
| Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
| Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice | Q32085363 | ||
| Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. | Q32085397 | ||
| Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice | Q33236495 | ||
| Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. | Q33947837 | ||
| Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice | Q34142722 | ||
| Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. | Q34277079 | ||
| Anti-inflammatory properties of a platelet-activating factor acetylhydrolase | Q34307399 | ||
| Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records | Q34599640 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Low-density lipoprotein receptor--its structure, function, and mutations | Q35806339 | ||
| Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia | Q35806352 | ||
| Insulin resistance and PPAR insulin sensitizers | Q36645909 | ||
| Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets | Q36721566 | ||
| The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. | Q37079828 | ||
| PROactive: time for a critical appraisal | Q37122745 | ||
| HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis | Q37156017 | ||
| Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice | Q37242527 | ||
| Reassessing the cardiovascular risks and benefits of thiazolidinediones | Q37264420 | ||
| Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance | Q39935597 | ||
| Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha | Q40080032 | ||
| Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line | Q40219233 | ||
| Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide | Q40426965 | ||
| Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. | Q40464074 | ||
| Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage | Q40531038 | ||
| Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma | Q40713487 | ||
| Connective tissue growth factor. Friend or foe? | Q41596354 | ||
| Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells | Q43513110 | ||
| High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization | Q43653251 | ||
| Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study | Q43670632 | ||
| The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus | Q43699554 | ||
| Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE. | Q43843334 | ||
| Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy | Q44034689 | ||
| Antiinflammatory and antiarteriosclerotic effects of pioglitazone | Q44201670 | ||
| Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study | Q44238610 | ||
| Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model | Q44287903 | ||
| A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus | Q44480091 | ||
| Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase | Q44628017 | ||
| Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients | Q45064729 | ||
| Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects | Q46601696 | ||
| Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone | Q46620643 | ||
| Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome | Q46801114 | ||
| Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors | Q46930716 | ||
| Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting | Q46940170 | ||
| Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques | Q50714707 | ||
| Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. | Q51112774 | ||
| Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. | Q51552529 | ||
| Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia | Q59624472 | ||
| Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice | Q64381202 | ||
| Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates | Q70169343 | ||
| Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation | Q71789521 | ||
| Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux | Q73596081 | ||
| Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study | Q79615264 | ||
| Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice | Q80092264 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | knockout mouse | Q1364740 |
| atherosclerosis | Q12252367 | ||
| Eomesodermin | Q21981066 | ||
| P304 | page(s) | 2007–2014 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone | |
| P478 | volume | 174 |
| Q35395455 | Acute exercise activates AMPK and eNOS in the mouse aorta |
| Q36851491 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. |
| Q39379798 | Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. |
| Q33885504 | Crossroads between peripheral atherosclerosis, western-type diet and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral arterial disease |
| Q43065142 | Differential effects of pioglitazone on advanced atherosclerotic lesions |
| Q27311648 | Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the Wnt signaling pathway |
| Q34980214 | Innate immunity and monocyte-macrophage activation in atherosclerosis. |
| Q38517043 | Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis |
| Q30551530 | Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid. |
| Q38887788 | New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice. |
| Q37790384 | PPARs as therapeutic targets in cardiovascular disease |
| Q37627571 | PPARγ and Its Role in Cardiovascular Diseases. |
| Q36612212 | Pioglitazone attenuates valvular calcification induced by hypercholesterolemia |
| Q42849811 | SorLA modulates atheroprotective properties of CLA by regulating monocyte migration |
Search more.